In contrast, the SYNERGY-NASH trial (NCT04166773) investigated tirzepatide, a dual GLP-1/GIP receptor agonist, in patients with biopsy-confirmed MASH and fibrosis stages F2–F3 [77]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.